

ORAL PRESENTATION

Open Access

# Effects of long-term proBNP cardiac gene delivery in experimental hypertensive heart disease

Alessandro Cataliotti\*, Jason M Tonne, Guido Boerrigter, Salvatore Mangiafico, John C Burnett, Yasuhiro Ikeda

From 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications  
Halle, Germany. 24-26 June 2011

## Background

In the current study, we tested the effects of sustained cardiac proBNP gene delivery on blood pressure (BP), cardiac function and remodeling in spontaneously hypertensive rats (SHR).

## Methods

We used the myocardium-tropic adeno-associated virus serotype 9 (AAV9) vector to achieve continuously enhanced cardiac rat proBNP expression. \* $p < 0.05$  vs treated rats.

## Results

In SHR, a single systemic administration of AAV9 vector allowed longterm, cardiac BNP overexpression with an increase in plasma BNP levels as compared with untreated SHR ( $433.3 \pm 17$  vs  $60.6 \pm 15^*$  pg/ml). This further resulted in reductions in systolic ( $121 \pm 11$  vs  $184 \pm 13^*$  mm Hg) and diastolic ( $103 \pm 5$  vs  $148 \pm 24^*$  mm Hg) BP for nine months after injection as compared with untreated SHR. Left ventricular (LV) thickness ( $1.87 \pm 0.1$  vs  $2.16 \pm 0.3^*$  mm), LV end-systolic dimensions ( $3.96 \pm 0.3$  vs  $4.66 \pm 0.6^*$  mm) and LV mass ( $0.4 \pm 0.01$  vs  $0.49 \pm 0.01^*$  gr) were reduced, while ejection fraction was increased ( $83 \pm 2$  vs  $74 \pm 4^*$  %) in BNP-treated compared to untreated SHR. Circumferential systolic strain ( $-5.04 \pm 0.4$  vs  $-3.74 \pm 0.4^*$  %) and strain rate of the early phase of diastole ( $-4.57 \pm 2.1$  vs  $-2.41 \pm 1.3$  1/s) were improved in BNP-treated compared with controls. Importantly, the improvement in cardiac function and structure also resulted in a significant increase in survival ( $p < 0.001$  vs untreated SHR). Non-cardiac overexpression of BNP, via AAV2 vector, was not associated with changes in plasma BNP

and BP in SHR. Nevertheless, normotensive Wistar rats injected with AAV9 proBNP vector showed significantly reduced heart/body weights ( $0.31 \pm 0.1$  vs  $3.9 \pm 0.1^*$  %) four weeks after injection without BP reduction compared to untreated rats.

## Conclusion

AAV9 vector facilitates sustained cardiac proBNP overexpression improves both systolic and diastolic cardiac function in hypertensive heart disease. Long-term proBNP delivery improved survival in SHR. The effects on cardiac structure and function occurred independently of BP lowering effects in normotensive Wistar rats.

Published: 1 August 2011

doi:10.1186/1471-2210-11-S1-O16

Cite this article as: Cataliotti *et al.*: Effects of long-term proBNP cardiac gene delivery in experimental hypertensive heart disease. *BMC Pharmacology* 2011 **11**(Suppl 1):O16.

### Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



\* Correspondence: [cataliotti.alessandro@mayo.edu](mailto:cataliotti.alessandro@mayo.edu)

Mayo Clinic, Cardioresenal Research Laboratory, 200 First St SW, Rochester, MN 55905, USA